查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363348

多形性膠質母細胞瘤治療市場規模、佔有率和趨勢分析報告：2023-2030 年按治療、藥物類別、最終用途、地區和細分市場進行的預測

Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

多形性膠質母細胞瘤治療市場的成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球多形性膠質母細胞瘤治療市場規模預計將達到 51 億美元。

預計2023年至2030年年複合成長率為9.7%。該市場的推動因素是新型療法和聯合治療的患病不斷上升以及核准不斷提高。

近年來，由於創新產品的推出、有利的指導方針導致大型製藥企業對市場的興趣增加以及罹患率上升，該行業經歷了快速成長。例如，百時美施貴寶、CNS Pharmaceuticals 和拜耳正在開發治療多形性膠質母細胞瘤的新產品。未來年度，這些產品可能會加劇市場上競爭公司之間的敵意。

此外，各公司正在合作開發新的治療方法。例如，2019年10月，臨床階段生物技術公司Advaxis, Inc.宣佈在多形性膠質母細胞瘤小鼠腫瘤模型中使用其Lm技術，研究、開發和商業化一種新型免疫療法。加州。研究人員和市場參與者之間加強合作預計將支持多形性膠質母細胞瘤新型有效治療方案的開發。

現有公司積極收購擁有研發線產品的新公司，使其產品系列多樣化。例如，2019 年 5 月，默克宣布以 11 億美元領先收購Peloton Therapeutics，使其能夠獲得其在研膠質母細胞瘤治療藥物 PT2977。我們相信此次收購將加強我們的產品線並提高我們未來的產生收入能力。

世界各地的政府和非政府組織正在做出各種努力，透過教育受多形性膠質母細胞瘤罹患的人們以及為研發活動和治療籌集資金來提高人們的認知。這些配合措施預計將推動多形性膠質母細胞瘤(GBM) 的成長）預測期內的治療市場。例如，行動訊息平台 Ping Mobile 發起了一項行動活動，以提高人們對腦腫瘤的認知。這將有助於提高人們對多形性膠質母細胞瘤的認知，並激勵多形性膠質母細胞瘤研究工作的捐款。

美國腦腫瘤協會、加拿大腦腫瘤基金會和治癒腦癌基金會等組織也正在進行一系列宣傳活動，以提高大眾對腦腫瘤的認知。在英國，三月是腦腫瘤意識月，由腦腫瘤研究成員組織進行活動。該活動的主要目的是提高人們對腦腫瘤研究缺乏資金的認知，並幫助人們了解腦腫瘤及其治療方法。此外，Novocure 在腦腫瘤宣傳月期間開展了一系列活動，以提高對多形性膠質母細胞瘤的認知。

多形性膠質母細胞瘤治療市場報告亮點

  • 從治療方法來看，放射線治療佔市場主導地位，2022年銷售佔有率為37.0%。這是由於存活率提高，因為放射線治療通常被推薦為第一線治療或與化療或手術結合。
  • 按藥品類別分類，其他細分市場在 2022 年佔據最大銷售佔有率。此部分包括Everolimus、皮質類固醇和 5-氨基乙醯丙酸 (5-ALA)。
  • 2022年，醫院部門在多形性膠質母細胞瘤治療市場中佔據最大的收益佔有率，預計在預測期內將保持主導地位。患者更喜歡醫院，因為他們可以獲得護理和便利。
  • 由於學名藥替Temozolomide進入市場、經濟改善、老年人口增加以及醫療保健領域投資增加等多種要素，亞太地區在預測期內將錄得最快的成長率，達到11.1%。
  • 北美地區佔比最大，2022年為43.4%。政府對醫療保健領域發展的支持、對罕見疾病的高度認知、優質醫療設施的便利性、優惠的報銷政策等是推動該地區市場成長的主要要素。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 多形性膠質母細胞瘤治療市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 產業價值鏈分析
    • 贖回框架
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 多形性膠質母細胞瘤治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 多形性膠質母細胞瘤治療市場：按治療方法估計和趨勢分析

  • 多形性膠質母細胞瘤治療市場：重點
  • 多形性膠質母細胞瘤治療市場：2022 年和 2030 年治療趨勢和市場佔有率分析
  • 外科手術
  • 放射治療
  • 化療
  • 標靶治療
  • 腫瘤治療 (TTF) 治療
  • 免疫療法

第5章 多形性膠質母細胞瘤治療市場：依藥物類別估計與趨勢分析

  • 多形性膠質母細胞瘤治療市場：重點
  • 多形性膠質母細胞瘤治療市場：2022 年和 2030 年藥物類別趨勢和市場佔有率分析
  • Temozolomide
  • Bevacizumab
  • Lomustine
  • Carmustine晶圓
  • 其他

第6章 多形性膠質母細胞瘤治療市場：依最終用途的估計與趨勢分析

  • 多形性膠質母細胞瘤治療市場：重點
  • 多形性膠質母細胞瘤治療市場：2022 年和 2030 年最終用途趨勢和市場佔有率分析
  • 醫院
  • 診所
  • 門診手術中心

第7章 多形性膠質母細胞瘤治療市場：區域估計和趨勢分析

  • 區域預測
  • 按地區分類的多形性膠質母細胞瘤治療市場：重點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Merck & Co., Inc.
    • Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Amgen, Inc.
    • Arbor Pharmaceuticals, LLC
    • Amneal Pharmaceuticals
    • Karyopharm Therapeutics, Inc.
Product Code: GVR-4-68039-527-3

Glioblastoma Multiforme Treatment Market Growth & Trends:

The global glioblastoma multiforme treatment market size is expected to reach USD 5.10 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 9.7% from 2023 to 2030. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.

In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.

Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company's Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.

Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.

Various initiatives undertaken by the governments and non-government bodies across the globe to increase awareness by educating people living with glioblastoma multiforme and raising funds for R&D activities and treatment are expected to fuel the glioblastoma multiforme (GBM) treatment market growth during the forecast period. For instance, Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps in raising awareness about glioblastoma multiforme and motivating people to donate money for glioblastoma multiforme research activities.

Organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The main aim of the campaign is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Moreover, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month.

Glioblastoma Multiforme Treatment Market Report Highlights:

  • Based on treatment, in 2020, radiation therapy dominated the market with a revenue share of 37.0% in 2022, owing to improved survival rates, as radiation therapy is most often recommended as the first line of treatment or in combination with chemotherapy and surgery
  • By drug class, the others segment accounted for the largest revenue share in 2022. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)
  • The hospital segment held the largest revenue share in the glioblastoma multiforme treatment market in 2022 and is anticipated to maintain its leading position during the forecast period. Patients prefer hospitals in terms of treatment accessibility and convenience
  • Asia Pacific is expected to register the fastest growth rate of 11.1% over the forecast period, owing to various factors such as the entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector
  • North America accounted for the largest share of 43.4% in 2022. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility to quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. Drug class
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Glioblastoma Multiforme Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
    • 3.4.2. Market Restraint Analysis
  • 3.5. Glioblastoma Multiforme Treatment Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape

Chapter 4. Glioblastoma Multiforme Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
  • 4.2. Glioblastoma Multiforme Treatment Market: Treatment Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Surgery
    • 4.3.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Radiation Therapy
    • 4.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Tumor Treating Field (TTF) Therapy
    • 4.7.1. Tumor treating field (TTF) therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Immunotherapy
    • 4.8.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Glioblastoma Multiforme Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
  • 5.2. Glioblastoma Multiforme Treatment Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Temozolomide
    • 5.3.1. Temozolomide market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Bevacizumab
    • 5.4.1. Bevacizumab market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Lomustine
    • 5.5.1. Lomustine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Carmustine Wafers
    • 5.6.1. Carmustine Wafers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Glioblastoma Multiforme Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Glioblastoma Multiforme Treatment Market: Key Takeaways
  • 6.2. Glioblastoma Multiforme Treatment Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Clinics
    • 6.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Glioblastoma Multiforme Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Glioblastoma Multiforme Treatment Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Merck & Co., Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Teva Pharmaceutical Industries Ltd.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Sun Pharmaceutical Industries Ltd.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Hoffmann-La Roche Ltd.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pfizer, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Amgen, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Arbor Pharmaceuticals, LLC
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Amneal Pharmaceuticals
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Karyopharm Therapeutics, Inc.
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 North America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 U.S. glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Canada glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Europe glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Germany glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Germany glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 UK glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 UK glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 UK glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 France glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 France glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Italy glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Italy glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Italy glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Spain glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Spain glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Spain glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Sweden glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Sweden glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Sweden glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Norway glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 Norway glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Norway glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Denmark glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Denmark glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Denmark glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 44 China glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 China glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 China glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Japan glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Japan glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Japan glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 India glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 India glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 India glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Thailand glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Thailand glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Thailand glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 South Korea glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 South Korea glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Australia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Australia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Australia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 Latin America glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Latin America glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Brazil glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Brazil glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 Mexico glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 Mexico glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 74 Argentina glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa glioblastoma multiforme treatments market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 81 South Africa glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 85 UAE glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 87 UAE glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait glioblastoma multiforme treatments market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait glioblastoma multiforme treatments market, by drug class, 2018 - 2030 (USD Million)
  • Table 90 Kuwait glioblastoma multiforme treatments market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Glioblastoma multiforme treatments: Market outlook
  • Fig. 9 Glioblastoma multiforme treatments: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Glioblastoma multiforme treatments market driver impact
  • Fig. 15 Glioblastoma multiforme treatments market restraint impact
  • Fig. 16 Glioblastoma multiforme treatments market strategic initiatives analysis
  • Fig. 17 Glioblastoma multiforme treatments market: Treatment movement analysis
  • Fig. 18 Glioblastoma multiforme treatments market: Treatment outlook and key takeaways
  • Fig. 19 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Tumor treating field (TTF) therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Immunotherapy therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Glioblastoma multiforme treatments market: Drug class movement analysis
  • Fig. 26 Glioblastoma multiforme treatments market: Drug class outlook and key takeaways
  • Fig. 27 Temozolomide market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Bevacizumab market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Lomustine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Carmustine wafers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Glioblastoma multiforme treatments market: End-use movement analysis
  • Fig. 33 Glioblastoma multiforme treatments market: End-use outlook and key takeaways
  • Fig. 34 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Ambulatory Surgical Centers market estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Global glioblastoma multiforme treatments market: Regional movement analysis
  • Fig. 38 Global glioblastoma multiforme treatments market: Regional outlook and key takeaways
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)